Tirapazamine-cisplatin: the synergy

British Journal of Cancer
U GatzemeierA Rey

Abstract

Tirapazamine is a novel bioreductive agent with selective cytotoxicity against hypoxic tumour cells. Synergy with cisplatin and other chemotherapeutic agents has been shown in preclinical trials. Pharmacokinetic studies of tirapazamine have revealed that exposure increases with dose over the range of 18-450 mg m(-2) for a single dose and of 9-390 mg m(-2) for multiple doses. Plasma clearance is high. Tirapazamine has been clinically tested in combination with cisplatin at escalating doses in a phase I trial and at therapeutic doses in three separate phase II trials in patients with advanced non-small-cell lung cancer (NSCLC) in 11 study centres. Limiting toxicity for tirapazamine at an intravenous dose of 390 mg m(-2) was acute, reversible hearing loss. Other frequently observed side-effects included muscle cramping and gastrointestinal symptoms. Tirapazamine did not cause myelosuppression, and no toxic deaths were reported in these trials. The anti-tumour efficacy against previously untreated, advanced NSCLC was evaluated by cumulative intent-to-treat analysis of 132 patients. The objective response rate (confirmed by two independent measurements) was 25% [confidence interval (CI) 17.8-33.33], with a median survival of 38.9 we...Continue Reading

Citations

Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A TaammaE Cvitkovic
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Victor M AquinoMark Bernstein
Jul 12, 2007·Journal of Cancer Research and Clinical Oncology·Markus AdamCarsten Nieder
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Werner ScheithauerDieter Depisch
Jun 29, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·F C MalufD R Spriggs
Dec 20, 2002·The Oncologist·Louis B HarrisonDaniel Shasha
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K FizaziJ P Armand
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Yves DouillardSteven E Benner
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James CarmichaelChristophe Martin
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K FizaziP Ruffié

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.